Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 2/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.56 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.56 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.56 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.56 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.56 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MARS1 | P56192 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.51 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PRKACA | P17612 | 2/20 | 0.50 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9300768 | 1.00 | PRKAB2 (0.56) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL19889158 | 0.91 | ALDH1A1 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL13597931 | 0.91 | ALDH1A1 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31685764 | 0.91 | ALDH1A1 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL4425824 | 0.91 | ALDH1A1 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL23982402 | 0.91 | ALDH1A1 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL8205660 | 0.91 | ALDH1A1 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL11423681 | 0.91 | ALDH1A1 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL10033986 | 0.91 | ALDH1A1 (0.65) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL2585546 | 0.90 | ADORA1 (0.60) | ALDH1A1ADORA1SMN1; SMN2ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362244-B2 | Method for producing nucleoside derivatives | AJINOMOTO CO., INC. (JP) | 2013-01-29 | — | — | US | claimed |
| US-20070282104-A1 | METHOD FOR PRODUCING NUCLEOSIDE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-12-06 | — | — | US | claimed |
| EP-1849786-A1 | METHOD FOR PRODUCING NUCLEOSIDE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2007-10-31 | — | — | EP | claimed |
| US-8362244-B2 | Method for producing nucleoside derivatives | AJINOMOTO CO., INC. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20070282104-A1 | METHOD FOR PRODUCING NUCLEOSIDE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2007-12-06 | — | — | US | disclosed |
| EP-1849786-A1 | METHOD FOR PRODUCING NUCLEOSIDE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-6699979-B2 | PREPARED VIA A STEREOSPECIFIC SN2 NUCLEOPHILIC ATTACK OF A PHOSPHODIESTER, OR PHOSPHOROTHIOATE, ON THE 3' POSITION OF A XYLONUCLEOTIDE; USEFUL IN ANTISENSE OR PROBE TECHNOLOGY | ISIS PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030204080-A1 | Methods for producing nucleoside derivatives and intermediates therefor | AJINOMOTO CO. INC (JP) | 2003-10-30 | — | — | US | disclosed |
| US-20030204079-A1 | Process for producing 2', 3'-diethy substituted nucleoside derivatives | AJINOMOTO CO., INC (JP) | 2003-10-30 | — | — | US | disclosed |
| US-6579976-B2 | Producing compounds having sugar-moiety hydroxyl groups or halogen atoms reduced in nucleic acids by allowing O-thiocarbonyl derivatives or halogenated derivatives in the sugar-moiety react with hypophosphorous acids or salts | AJINOMOTO CO., INC. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-20030004330-A1 | Methods for producing nucleoside derivatives and intermediates therefor | AJINOMOTO CO. INC (JP) | 2003-01-02 | — | — | US | disclosed |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. | 2001-07-19 | — | — | US | disclosed |
| US-6239265-B1 | FOR RESEARCH AND DIAGNOSIS | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | disclosed |
| EP-0999218-A1 | Process for producing nucleoside derivatives | Ajinomoto Co., Inc. (JP) | 2000-05-10 | — | — | EP | disclosed |
| US-5852188-A | Oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5521302-A | NUCLEOPHILIC REACTION OF PHOSPHATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5466793-A | Catalytic reducing of a nucleoside with hydrogen in the presence of palladium and recovering | AJINOMOTO CO., INC. (JP) | 1995-11-14 | — | — | US | disclosed |
| US-5290927-A | Process for preparing 2',3'-dideoxyadenosine | AJINOMOTO CO., INC. (JP) | 1994-03-01 | — | — | US | disclosed |
| US-5212295-A | Monomers for preparation of oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS (US) | 1993-05-18 | — | — | US | disclosed |
| US-5106962-A | Reacting nucleosides with viologens in the presence of base | AJINOMOTO CO., INC. (JP) | 1992-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004330-A1 | Methods for producing nucleoside derivatives and intermediates therefor | DCTD, ADAR, IMPDH1 | PRKAB2 2523/4885PRKAG1 2464/4885PRKAA2 1525/4885 |
| US-20070282104-A1 | METHOD FOR PRODUCING NUCLEOSIDE DERIVATIVES | SLC29A2, SLC29A1, NUDT1 | PRKAB2 2653/4885PRKAG1 3144/4885PRKAA2 3411/4885 |
| US-20030204079-A1 | Process for producing 2', 3'-diethy substituted nucleoside derivatives | RNGTT, DOHH, NT5C3B | PRKAB2 839/4885PRKAG1 1380/4885PRKAA2 901/4885 |
| US-20030204080-A1 | Methods for producing nucleoside derivatives and intermediates therefor | DCTD, ADAR, IMPDH1 | PRKAB2 2523/4885PRKAG1 2464/4885PRKAA2 1525/4885 |
| US-20010008936-A1 | Oligonucleotides having chiral phosphorus linkages | RNGTT, PNP, PSPH | PRKAB2 1373/4885PRKAG1 1423/4885PRKAA2 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.